IDXX Stock Chart & Stats
$10354.39
$0.00(0.00%)
At close: 4:00 PM EDT
$10354.39
$0.00(0.00%)
Day’s Range― - ―
52-Week Range$8,808.01 - $14,152.50
Previous CloseN/A
Volume0.00
Average Volume (3M)9.00
Market Cap
$763.87B
Enterprise Value$45.95K
Total Cash (Recent Filing)$196.93M
Total Debt (Recent Filing)$669.00M
Price to Earnings (P/E)40.9
Beta0.42
Next Earnings
Nov 03, 2026EPS Estimate
64.19Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)6.53
Shares Outstanding78,882,996
10 Day Avg. Volume1
30 Day Avg. Volume9
Financial Highlights & Ratios
PEG Ratio2.31
Price to Book (P/B)33.75
Price to Sales (P/S)12.59
P/FCF Ratio51.44
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$11,961.15Price Target Upside15.52% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering6
EPS Forecast (FY)252.63
Revenue Forecast (FY)$81.22B
Bulls Say, Bears Say
Bulls Say
Recurring Consumables / Installed BaseAn installed base of in‑clinic analyzers and reference labs drives recurring consumable sales and ongoing test volumes. That lock‑in generates predictable, high‑margin revenue streams, smoothing cash flow and supporting durable margins and long‑term monetization as utilization scales.
Strong Cash Generation And FCF ConversionRobust operating cash flow and high free cash flow conversion give the company financial flexibility to fund R&D, capex, and buybacks without heavy external financing. Reliable FCF supports sustained reinvestment, shareholder returns, and balance sheet resilience through economic cycles.
Product Innovation & Premium Instrument AdoptionAccelerating placements of premium instruments (inVue) and rising adoption of diagnostics like Cancer Dx expand the high‑value installed base and consumable attach. This product‑led momentum increases lifetime customer value and supports structural recurring revenue growth beyond cyclical service demand.
Bears Say
Growth Normalization / Maturing ProfileTop‑line expansion has moderated as the business matures, reducing the potential for outsized organic growth. With less runway for rapid revenue acceleration, future EPS gains rely more on margin expansion, buybacks, and new product adoption, increasing sensitivity to execution and market cycles.
U.S. Clinical & Wellness Visit WeaknessSustained declines in U.S. clinic and wellness visits suppress lab utilization and in‑clinic testing volumes, directly reducing consumable pull‑through and reference lab revenue. If consumer pressures or muted pet additions persist, this demand drag could constrain recurring revenue for multiple quarters.
Rising Operating Expenses For InvestmentsManagement is increasing commercial, R&D and IT spending, which will temper near‑term margin expansion despite gross margin tailwinds. These sustained investments require commensurate revenue upside to preserve operating leverage; absent that, profit expansion could be limited.
Idexx Laboratories News
IDXX FAQ
What was Idexx Laboratories’s price range in the past 12 months?
Idexx Laboratories lowest stock price was $8808.01 and its highest was $14152.50 in the past 12 months.
What is Idexx Laboratories’s market cap?
Idexx Laboratories’s market cap is $763.87B.
When is Idexx Laboratories’s upcoming earnings report date?
Idexx Laboratories’s upcoming earnings report date is Nov 03, 2026 which is in 90 days.
How were Idexx Laboratories’s earnings last quarter?
Idexx Laboratories released its earnings results on Aug 04, 2026. The company reported $73.658 earnings per share for the quarter, beating the consensus estimate of $68.017 by $5.641.
Is Idexx Laboratories overvalued?
According to Wall Street analysts Idexx Laboratories’s price is currently Undervalued.
Does Idexx Laboratories pay dividends?
Idexx Laboratories does not currently pay dividends.
What is Idexx Laboratories’s EPS estimate?
Idexx Laboratories’s EPS estimate is 64.19.
How many shares outstanding does Idexx Laboratories have?
Idexx Laboratories has 78,882,996 shares outstanding.
What happened to Idexx Laboratories’s price movement after its last earnings report?
Idexx Laboratories reported an EPS of $73.658 in its last earnings report, beating expectations of $68.017. Following the earnings report the stock price went up 7.772%.
Which hedge fund is a major shareholder of Idexx Laboratories?
Currently, no hedge funds are holding shares in MX:IDXX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Idexx Laboratories Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$11,961.15 (15.52% Upside)
$11,961.15 (15.52% Upside)
Blogger Sentiment
Bullish
MX:IDXX Sentiment 71%
Sector Average 65%
Sector Average 65%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-1.02%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
5.35%
Trailing 12-Months
Company Description
Idexx Laboratories
IDEXX Laboratories, Inc. is a global enterprise focused on creating, producing, and distributing a wide array of products and services. Its primary client base includes companion animal veterinary practices, the livestock and poultry industries, dairy operations, and water quality testing sectors. The company organizes its operations across several key divisions: the Companion Animal Group (CAG), Water Quality Products, Livestock, Poultry, and Dairy (LPD), and additional segments. For companion animals, IDEXX offers a comprehensive suite of point-of-care veterinary diagnostic tools, such as instruments, consumables, and rapid assay kits. It also provides reference laboratory diagnostic and consultation services, alongside practice management and diagnostic imaging solutions for veterinarians. Furthermore, the company supports the biomedical research community with health monitoring, biological materials testing, and laboratory animal diagnostic instruments and services. In the livestock, poultry, and dairy markets, IDEXX supplies diagnostic and health-monitoring solutions. Its water testing portfolio includes products designed to detect various microbiological contaminants, notably the Colilert, Colilert-18, and Colisure tests for total coliforms and E. coli, as well as Enterolert, Pseudalert, Filta-Max, Filta-Max xpress, Legiolert, and Quanti-Tray products. Beyond these, IDEXX extends its reach to human point-of-care medical diagnostics, offering electrolyte and blood gas analyzers, and SARS-CoV-2 RT-PCR tests. Other key offerings encompass in-clinic chemistry, blood and urine chemistry, hematology, and SediVue Dx analyzers, as well as SNAP rapid assay test kits. Veterinary software and services for both independent clinics and large corporate veterinary groups are also part of its offerings. The company distributes its extensive product and service catalog through its own dedicated marketing, customer service, sales, and technical service teams, supplemented by independent distributors and other resellers. IDEXX Laboratories, Inc. was established in 1983 and maintains its headquarters in Westbrook, Maine.
IDXX Company Deck
IDXX Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed a strongly constructive operational and financial picture: solid organic revenue growth (~9% Q2), recurring CAG Diagnostics strength, robust margin and EPS expansion, strong free cash flow and aggressive capital returns, plus clear product and innovation momentum (inVue Dx, Cancer Dx, Catalyst SDMA). Offsetting items include continued pressure on U.S. clinic and wellness visits, a Q2 instrument revenue lap effect, foreign-exchange headwinds, and planned incremental investments that will temper near-term margin gains. Overall, the positive drivers — durable recurring revenue expansion, margin gains, cash generation, and multiple innovation milestones — materially outweigh the cited headwinds.View all MX:IDXX earnings summariesIDXX Revenue Breakdown
91.86% CAG
4.67% Water
3.06% LPD
0.41% Other
IDXX Stock 12 Month Forecast
Average Price Target
$11,961.15
▲(15.52% Upside)